Urokinase-type plasminogen activator receptor binding peptides and methods of use
AssigneesThe United States Government as represented by the Department of Veterans Affairs, Case Western Reserve University
InventorEvi X Stavrou
Life of this patent
Estimating the term…
Abstract
Disclosed herein, are peptides that bind urokinase-type plasminogen activator receptors. The peptides may comprise amino acid sequences of IPPWEAPK (SEQ ID NO: 1), DLAQCQTPTQAAPPTPVSPR (SEQ ID NO: 2), or LHVPLMPAQPAPPK (SEQ ID NO: 3), or retro-inverso amino acid sequences of the above enumerated sequences. Also described herein, are methods of administering compounds comprising peptides that bind urokinase-type plasminogen activator receptors to subjects for the treatment of ovarian cancer and improving wound closure.
Claims28
A peptide comprising an amino acid sequence of at least 60% identity to the amino acid sequence of IPPWEAPK (SEQ ID NO:
- 1) or a retro-inverso amino acid sequence of SEQ ID NO:
- 1, wherein the peptide binds urokinase-type plasminogen activator receptor (uPAR).
A peptide comprising an amino acid sequence of at least 60% identity to the amino acid sequence of DLAQCQTPTQAAPPTPVSPR (SEQ ID NO:
- 2) or a retro-inverso amino acid sequence of SEQ ID NO:
- 2, wherein the peptide binds urokinase-type plasminogen activator receptor (uPAR).
The peptide of claim 6 or 7, wherein the amino acid sequence comprises a Q at position 10, a P at position 14, a P at position 16, and a V at position 17 of SEQ ID NO:
- 2.
A peptide comprising an amino acid sequence of at least 60% identity to the amino acid sequence of LHVPLMPAQPAPPK (SEQ ID NO:
- 3) or a retro-inverso amino acid sequence of SEQ ID NO:
- 3, wherein the peptide binds urokinase-type plasminogen activator receptor (uPAR).
The peptide of any of the preceding claims, wherein the peptide is linear or cyclized.
The peptides of any of the preceding claims, wherein the peptide comprises one or more polyethylene glycol moieties (PEG).
Dependencies are inferred from the claim text.